- Home
- HTH vs NVCR Comparison
HTH vs NVCR Comparison
Compare HTH & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HTH
- NVCR
- Stock Information
- Founded
- HTH 1998
- NVCR 2000
- Country
- HTH United States
- NVCR Jersey
- Employees
- HTH N/A
- NVCR N/A
- Industry
- HTH Major Banks
- NVCR Medical/Dental Instruments
- Sector
- HTH Finance
- NVCR Health Care
- Exchange
- HTH Nasdaq
- NVCR Nasdaq
- Market Cap
- HTH 2.0B
- NVCR 1.8B
- IPO Year
- HTH 2004
- NVCR 2015
- Fundamental
- Price
- HTH $31.95
- NVCR $16.11
- Analyst Decision
- HTH Hold
- NVCR Buy
- Analyst Count
- HTH 3
- NVCR 5
- Target Price
- HTH $34.50
- NVCR $26.60
- AVG Volume (30 Days)
- HTH 420.4K
- NVCR 955.2K
- Earning Date
- HTH 10-24-2024
- NVCR 10-30-2024
- Dividend Yield
- HTH 2.13%
- NVCR N/A
- EPS Growth
- HTH N/A
- NVCR N/A
- EPS
- HTH 1.63
- NVCR N/A
- Revenue
- HTH $1,169,826,000.00
- NVCR $577,738,000.00
- Revenue This Year
- HTH N/A
- NVCR $19.13
- Revenue Next Year
- HTH $0.70
- NVCR $5.33
- P/E Ratio
- HTH $19.62
- NVCR N/A
- Revenue Growth
- HTH N/A
- NVCR 14.63
- 52 Week Low
- HTH $28.58
- NVCR $11.29
- 52 Week High
- HTH $35.66
- NVCR $24.74
- Technical
- Relative Strength Index (RSI)
- HTH 50.68
- NVCR 44.79
- Support Level
- HTH $32.40
- NVCR $17.28
- Resistance Level
- HTH $33.40
- NVCR $18.38
- Average True Range (ATR)
- HTH 0.84
- NVCR 1.12
- MACD
- HTH 0.09
- NVCR -0.04
- Stochastic Oscillator
- HTH 39.60
- NVCR 28.29
About HTH Hilltop Holdings Inc.
Hilltop Holdings Inc is a Dallas-based financial holding company. Its primary line of business is to provide business and consumer banking services from offices throughout Texas through the PlainsCapital Bank. The company also provides other financial products and services through its broker-dealer and mortgage origination segments. The company generates a majority of its revenue through its banking operations.
About NVCR NovoCure Limited
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.